US5296508A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Farnesylated tetrahydro-naphthalenols as hypolipidemic agents
Assignee: Bristol Myers Squibb Co
•
Filing: 1992-12-23
•
Granted: 1994-03-22
•
Expires: 2012-12-23
Abstract
Abstract The invention relates to novel farnesylated tetrahydro-naphthalenols, that inhibit HMGR activity which results in a decrease in serum total cholesterol, a decrease in LDL cholesterol levels, and inhibition of LDL oxidation. The farnesylated tetrahydro-naphthalenols of the present invention are thus useful for cholesterol/lipid lowering in cases of hypercholesterolemia, hyperlipidemia, and atherosclerosis.
Inventors
- 👤 Bradley C. Pearce
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-30 02:38
CPC Classifications
C; C07; C07C; C07C317/00; C07C317/16; C07C317/18; C07C309/00; C07C309/63; C07C309/64; C07C309/65; C07C39/00; C07C39/23; C07C43/00; C07C43/02; C07C43/20; C07C43/215; C07C43/23; C07C45/00; C07C45/61; C07C45/67; C07C45/673; C07C45/68; C07C49/00; C07C49/587; C07C49/703; C07C49/747; C07C49/753; C07C2602/00; C07C2602/02; C07C2602/04; C07C2602/10
Claims Analysis
Total Claims: 8
Claim 1
Independent Claim
54 words
The compound having the structural formula (II) ##STR6## wherein R 3 is a physiologically hydrolyzable ester; R 1 represents hydrogen, C 1 -C 10 lower alkyl, halogen, or OMe; R 2 represents hydrogen, C 1 -C 10 lower alkyl; and n is 1-3; or pharmaceutically acceptable acid addition salts, metal salts or solvates thereof.
Claim 2
Dependent Claim
54 words
The compound having the structural formula (II) ##STR6## wherein R 3 is a physiologically hydrolyzable ester; R 1 represents hydrogen, C 1 -C 10 lower alkyl, halogen, or OMe; R 2 represents hydrogen, C 1 -C 10 lower alkyl; and n is 1-3; or pharmaceutically acceptable acid addition salts, metal salts or solvates thereof.
Claim 3
Dependent Claim
14 words
The compound of claim 1 which is the racemic mixture at the C-2 position.
Claim 4
Dependent Claim
13 words
The compound of claim 1 which is the R-isomer at the C-2 position.
Claim 5
Dependent Claim
13 words
The compound of claim 1 which is the S-isomer at the C-2 position.
Claim 6
Dependent Claim
34 words
A pharmaceutical composition for treating hypercholesterolemia which comprises an effective amount of at least one compound of claim 1, or salt, hydrate or solvate thereof, in combination with a pharmaceutical acceptable carrier or diluent.
Claim 7
Independent Claim
72 words
The method of treating hyperlipidemia hypercholesterolemia, and LDL oxidation in a bird of mammal, which comprises administering to said bird or mammal a safe and effective amount of at least one compound having the Formula (II) ##STR7## wherein R 3 is a physiologically hydrolyzable ester; R 1 represents hydrogen, C 1 -C 10 lower alkyl, halogen or OMe; R 2 represents hydrogen, C 1 -C 10 lower alkyl; and n is 1-3.
Claim 8
Independent Claim
72 words
The method of treating hyperlipidemia hypercholesterolemia, and LDL oxidation in a bird of mammal, which comprises administering to said bird or mammal a safe and effective amount of at least one compound having the Formula (II) ##STR7## wherein R 3 is a physiologically hydrolyzable ester; R 1 represents hydrogen, C 1 -C 10 lower alkyl, halogen or OMe; R 2 represents hydrogen, C 1 -C 10 lower alkyl; and n is 1-3.
References Cited (Backward Citations)
US4680310A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1997-03-21 | 1997-09-20 | 1998-03-22 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2001-03-21 | 2001-09-20 | 2002-03-22 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2005-03-21 | 2005-09-20 | 2006-03-22 | $7700.00 | Window Closed / Lapsed |